Multiple Myeloma and Chronic Lymphocytic Leukemia: Commonalities and Differences in Biology and Therapy

References

• Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: new insights into biology and therapy. Annals of Int. Med. 1990; 113: 525–39
   Web of Science ®Google Scholar
• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma—new biologic insights and advances in therapy. Blood 1989; 73: 865–79
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Tesio L. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J. Clin. Invest. 1985; 76: 1243–51
   PubMed Web of Science ®Google Scholar
• Barlogie B., Alexanian R. Cellular aspects of myeloma: biologic and clinical implications. Multiple Myeloma and Other Paraprotein-aemias, I. W. Delamore. Churchill Livingstone Publishers, New York 1986; 154–168
   Google Scholar
• Berenson J., Wong R., Kim K., Brown N., Lichtenstein A. Evidence of peripheral blood B lymphocyte but not T lymphocyte involvement. Blood 1987; 70: 1550–53
   PubMed Web of Science ®Google Scholar
• MacKenzie M. R., Scibienski R., Paglieroni T. Characterization of an immunosuppressive human plasma cell line. Second International Workshop on Myeloma: Advances in Biology and Therapy. Houston, Texas 1989, April 6–8, 4, (abstract)
   Google Scholar
• Durie B. G. M., Grogan T. M. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood 1985; 66: 229–32
   PubMed Web of Science ®Google Scholar
• Epstein J., Barlogie B., Katzmann J., Alexanian R. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood 1988; 71: 861–65
   PubMed Web of Science ®Google Scholar
• Grogan T. M., Durie B. G. M., Spier C. Myelomonocytic antigen positive multiple myeloma. Blood 1989; 74: 763–69
   Google Scholar
• Epstein J., Xiao H., He X. Y. Markers of multiple hematopoietic cell lineages in multiple myeloma. N. Engl. J. Med. 1990; 322: 664–68
   PubMed Web of Science ®Google Scholar
• Van Camp B., Durie B. G. M., Spier C. Plasma cells in multiple myeloma express a natural killer cell-associated antigen [NKH-1;Leu-19]. Blood 1990; 76: 377–82
   PubMed Web of Science ®Google Scholar
• Merle-Beral H., Légac E., Chastang A., Michel A., Debré P., Binet J. L. Myelomonocytic and activation antigens in B-CLL. Fifth International Workshop on CLL. Barcelona, Spain 1991, April 26–28, 26, (abstract)
   Google Scholar
• Tassies D., Villamor N., Rovira M. Expression of myelomonocytic antigens in B-chronic lymphocytic leukemia: study in 47 patients. Fifth International Workshop on CLL. Barcelona, Spain 1991, April 26–28, 27, (abstract)
   Google Scholar
• Molica S., Dattilo A., Alberti A. Myelomonocytic associated antigens in B-chronic lymphocytic leukemia. Analysis of their clinical significance. Fifth International Workshop on CLL. Barcelona, Spain 1991, April 26–28, 28, (abstract)
   Google Scholar
• Woessner S., Florensa L., Vilà C. Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals frequent reactivity with some myelomonocytic associated antibodies. Fifth International Workshop on CLL. Barcelona, Spain 1991; 29, (abstract) April 26–28
   Google Scholar
• Bergsagel D. E., Bailey A. J., Langley G. R., McDonald R., White D., Miller A. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N. Engl. J. Med. 19792; 301: 743–48
   PubMed Web of Science ®Google Scholar
• Dewald G. E., Kyle R. A., Hicks G. A., Greipp P. R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood 1985; 66: 380–90
   PubMed Web of Science ®Google Scholar
• Gould J., Alexanian R., Goodacre A., Pathak S., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453–56
   PubMed Web of Science ®Google Scholar
• Han T., Ozer H., Sadamori N. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N. Engl. J. Med. 1984; 310: 288–92
   PubMed Web of Science ®Google Scholar
• Juliusson G., Oscier D. G., Fitchett M. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N. Engl. J. Med. 1990; 323: 720–24
   PubMed Web of Science ®Google Scholar
• Barlogie B., Alexanian R., Gehan E. Marrow cytometry and prognosis in myeloma. J. Clin. Invest. 1983; 72: 853–61
   PubMed Web of Science ®Google Scholar
• Sawyer J. R., Thomas E. L., Barlogie B. Identification of new chromosomal breakpoints in multiple myeloma (MM) by high resolution (HR) cytogenetic (CG) analysis. Blood 1990; 76: 371a, 1474, Suppl. (abstract)
   Google Scholar
• Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am. J. Med. 1986; 80: 841–43
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Durie B. G. M., Alberts D. S., Gerlach J. H., Cress A. E. Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein. Cancer Res. 1986; 46: 5125–30
   PubMed Web of Science ®Google Scholar
• Durie B., Baum V., Vela E., Mundy G. Abnormalities of chromosome 6q and osteoclast activating factor production in multiple myeloma. Blood 1986; 68: 208a, 710, Suppl. (abstract)
   Google Scholar
• Kawano M., Hiran T., Matsuda T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 322: 83–85
   Web of Science ®Google Scholar
• Klein B., Azhang X.-G., Jourdan M. Paracrine but not autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–26
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti G. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–93
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Bataille R., Jourdan M. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599–605
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X.-G., Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest. 1989; 84: 2008–11
   PubMed Web of Science ®Google Scholar
• Garrett L. R., Durie B. G. M., Nedwin G. E. Production of the bone resorbing cytokine lymphotoxin by culture human myeloma cells. N. Engl. J. Med. 1987; 317: 526–32
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto I., Iwato K. Interleukin-1-beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73: 1646–49
   PubMed Web of Science ®Google Scholar
• Cozzolino F., Torcia M., Aldinucci D. Production of interleukin-1 by bone marrow myeloma cells: its role in the pathogenesis of lytic bone lesions. Blood 1989; 74: 380–87
   PubMed Web of Science ®Google Scholar
• Brandt S., Bodine D., Dunbar C., Nienhuis A. Dysregulated Interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 1990; 86: 592–99
   PubMed Web of Science ®Google Scholar
• Klein B., Wijdenes J., Zhang X. G. Murine anti-interleukin-6 monoclonal antibody therapy in myeloma. Blood. 1991, in press
   Google Scholar
• Asano S., Okano A., Ozawa K. In vivo effects of recombinant human interleukin-6 in primates: Stimulated production of platelets. Blood 1990; 75: 1602–605
   PubMed Web of Science ®Google Scholar
• Foa R. Cytokines in B-CLL. Fifth International Workshop on CLL. Barcelona, Spain 1991; 10, (abstract) April 26–28
   Google Scholar
• De France T., Fluckiger A.-C., Rousset F., Banchereau J. In Vitro activation of B-CLL cells. Fifth International Workshop on CLL. Barcelona, Spain 1991; 13, (abstract) April 26–28
   Google Scholar
• Caligaris-Cappio F., Gottardi D., Gaidano M. G. Normal CD5 + B cells and their relationship to B-CLL. Fifth International Workshop on CLL. Barcelona, Spain 1991; 14, (abstract) April 26–28
   Google Scholar
• Selvanayagam P., Blick M., Narni F. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 1988; 71: 30–35
   PubMed Web of Science ®Google Scholar
• Neri A., Murphy J. P., Cro L. Ras oncogene mutation in multiple myeloma. J. Exp. Med. 1989; 170: 1715–25
   PubMed Web of Science ®Google Scholar
• Seremetis S., Inghirami G., Gerrero D. Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. Science 1989; 243: 660–63
   PubMed Web of Science ®Google Scholar
• Selvanayagam P., Goodacre A., Strong L., Saunders G., Barlogie B. Alterations of bcl-1 oncogene in human multiple myeloma. Proc. Am. Assoc. Can. Res. 1987; 28: 76, (abstract)
   Google Scholar
• Adachi M., Teffer A., Greipp P., Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J. Exp. Med. 1991; 171: 559–64
   Web of Science ®Google Scholar
• Durie B. G. M., Mason D. Y., Giles F. Expression of the BCL-2 oncogene protein in multiple myeloma. Blood 1990; 76: 347a, 1378, Suppl. (abstract)
   Google Scholar
• Juliusson G., Gahrton G. Cytogenetics in B-cell chronic lymphocytic leukemia. Fifth National Workshop on CLL. Barcelona, Spain 1991; 15, (abstract) April 26–28
   Google Scholar
• Broder S., Humphrey R., Durm M. Impaired synthesis of (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. N. Engl. J. Med. 1975; 293: 887–92
   PubMed Web of Science ®Google Scholar
• Hoover R. G., Hickman S., Gebel H. M., Rebbe N., Lynch R. G. Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma. J. Clin. Invest. 1981; 67: 308–11
   PubMed Web of Science ®Google Scholar
• Moore J. S., Hoover R. G., Besa E. C., Nowell P. C. Defective T cell-mediated, isotype-specific immunoglobulin regulation in B cell chronic lymphocytic leukemia. Blood 1988; 71: 1012–20
   PubMed Web of Science ®Google Scholar
• Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med. 1984; 310: 1353–56
   PubMed Web of Science ®Google Scholar
• Keating M., Kantarjian H., Talpaz M. Fludarabine; a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Kraut E., Crowley J., Grever M. Phase II study of Fludarabine Phosphate in multiple myeloma. Invest. New Drugs 1990; 8: 199–200
   PubMed Web of Science ®Google Scholar
• Mellstedt H., Ahre A., Bjorkholm M. Interferon therapy in myelomatosis. Lancet 1979; 1: 245–47
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Amadori S. Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy results of an Italian randomized study. N. Engl. J. Med. 1990; 322: 1430–34
   PubMed Web of Science ®Google Scholar
• Oken M. M., Kyle R. A., Greipp P. R., Kay N. E., Tsiatis A., O'Connell M. J. Alternating cycles of VBMCP with interferon (rIFN-alpha 2) in the treatment of multiple myeloma. Proc. Am. Soc. Clin. Oncol. 1988; 7: 868, (abstract)
   Google Scholar
• Rai K. R., Sawitsky A. Alpha Interferon (alF) and Erythropoietin (EPO): studies on their potential role in therapy of B-cell chronic lymphocytic leukemia (CLL). Fifth National Workshop on CLL. Barcelona, Spain 1991; 66, (abstract) April 26–28
   Google Scholar
• Montserrat E., Villamor N., Urbano-Ispizua A. Treatment of early stage B-chronic lymphocytic leukemia with Alpha-2b Interferon after Chlorambucil reduction of the tumoral mass. Fifth National Workshop on CLL. Barcelona, Spain 1991; 68, (abstract) April 26–28
   Google Scholar
• Bataille R., Grenier J., Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis and treatment—a prospective study of 160 patients. Blood 1984; 63: 468–76
   PubMed Web of Science ®Google Scholar
• Alexanian R., Barlogie B., Fritsche H. Beta-2-microglobulin in multiple myeloma. Am. J. Hematol. 1985; 20: 345–52
   PubMed Web of Science ®Google Scholar
• Klein B., Bataille R. Interleukin-6 is the major growth factor for human myeloma cells in vitro and in vivo and serum CRP level, reflecting IL-6 activity in vivo, is a strong prognosis factor in myeloma. Third International Workshop (Torino, Italy). 1991, April 9–12, 41, (abstract)
   Google Scholar
• Barlogie B., Smallwood L., Smith T., Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma like myeloma. Annals Int. Med. 1989; 110: 521–25
   PubMed Web of Science ®Google Scholar
• Rai K. R., Sawitsky A., Cronkite E. P. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–34
   PubMed Web of Science ®Google Scholar
• Binet J. L., Le Porrier M., Dighiero G. A clinical staging system for chronic lymphocytic leukemia. Cancer 1977; 40: 855–64
   PubMed Web of Science ®Google Scholar
• International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. Annals of Int. Med. 1989; 110: 236–38
   Web of Science ®Google Scholar